

January 2020 updates to medication prior authorizations and post service claim edits

Security Health Plan requires prior authorization (PA) and post service claim edits (PSCE) on certain medications in order to ensure coverage and payment for those services. A number of requirements have been added for 2020 as we work to make sure all care, services and treatments are medically necessary.

Security Health Plan will implement additional PAs January 1, 2020, which include:

Specialty Drugs in the office based and outpatient settings

- Zolgensma® (onasemnogene abeparvovec-xioi)
- Luxturna® (voretigene neparvovec-rzyl)
- Imlygic® (talimogene laherparepvec)
- Provenge® (sipuleucel-T)
- Spravato® (esketamine)

Magellan will implement additional PAs & PSCEs January 1, 2020, which include:

Specialty Drugs in the office based and outpatient settings

- Herceptin Hylecta® (trastuzumab-hyaluronidase-oysk)
- Panzyga® (intravenous immune globulin)
- Rituxan Hycela® (rituximab and hyaluronidase human)
- Iluvien® (fluocinonide acetonide)
- Ozurdex® (dexamethasone intravitreal implant)
- Retisert® (fluocinonide acetonide intravitreal)
- Herzuma® (trastuzumab)
- Mvasi® (bevacizumab-awwb)
- Ogivri® (trastuzumab-dkst)
- Ontruzant® (trastuzumab-dttb)
- Somatuline® (lanreotide)- **transitioning from Security PA to Magellan PA**
- Elzonris® (tagraxofusp-erzs)
- Gamifant® (emapalumab-lzsg)- **transitioning from Security PSCE to Magellan PA**
- Ultomiris® (ravulizumab-cwvz)
- Belrapzo® (bendamustine)
- Truxima® (rituximab-abbs)
- Tecentriq® (atezolizumab)
- Botox® (botulinum A toxin)– **Magellan PA will now be required in addition to PSCE**
- Dysport® (botulinum A toxin)- **Magellan PA will be now required in addition to PSCE**
- Myobloc® (botulinum B toxin)- **Magellan PA will now be required in addition to PSCE**
- Yutiq® (fluocinolone Acetonide)
- Libtayo® (cemiplimab-rwlc)- **transitioning from Security PA to Magellan PA**

- Lumoxiti[®] (moxetumomab pasudotox-tdfk)- **transitioning from Security PA to Magellan PA**
- Takhzyro[®] (lanadelumab-flyo)- **transitioning from Security PA to Magellan PA**
- Khapzory[®] (levoleucovorin)
- Trazimera[®] (trastuzumab-qyyp)
- Asparlas[®] (calaspargase pegol-mknl)
- Kanjinti[®] (trastuzumab-anns)
- Zilretta[®] (triamcinolone)

This is only the list of the new prior authorizations and post service claim edits required of members and providers to ensure payment for services. You can review the full list of medications that will require a prior authorization and/or post service claim edit on our website at www.securityhealth.org/providers/medical-pharmacy. If you have any questions, please contact Security Health Plan Provider Relations at **1-800-548-1224 (TTY: 711)**.